Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Amdocs Limited’s ( DOX - Analyst Report ) fourth quarter fiscal 2012 adjusted earnings per share (excluding special items) stood at 66 cents, beating the Zacks Consensus Estimate of 64 cents. The impressive outcome was primarily based on the stabilization of Amdocs’s business with its major client AT&T Inc. ( T - Analyst Report ) to some extent and the continuous double-digit growth in the emerging markets. The company has increased its Non-GAAP earnings per share forecast for the first quarter of fiscal 2013 and has authorized a repurchase plan of $500 million of ordinary shares without any expiry date.
Extension of Sprint Contract
Amdocs announced that it has extended its managed service contract with Sprint-Nextel Corp. ( S - Analyst Report ) till 2021 and has also added Virgin Mobile branded subscribers to its platform. The deal is envisioned to provide solid revenue visibility in North America over the long haul. Similar deals with Globe of Philippines, TIM Brazil in Latin America and the recently announced business support service deal with Russia’s VimpelCom will further enhance the growth prospect of the company in the emerging markets.
Fourth Quarter Results in Details
Quarterly net income, on a GAAP basis, was $98.0 million or 60 cents per share compared with a net income of $87.4 million or 49 cents per share in the prior-year quarter. Quarterly total revenue came in at $822.1 million, up 1.2% year over year, but it marginally missed the Zacks Consensus Estimate of $824 million.
Amdocs posted gross margin of 35.6% in the quarter against 35.3% in the year-ago quarter. Reported operating income was approximately $113.5 million, up 8.6% year over year. Again, operating margin was 13.8% against 12.9% in the prior-year quarter. At the end of the fourth quarter of fiscal 2012, total order backlog was $2,790 million compared with $2,760 million at the end of the previous quarter. In the reported quarter, Amdocs repurchased shares worth $106 million.
During fiscal 2012, Amdocs generated around $514.1 million in cash from operations compared with $535.5 million in the prior-year period. Free cash flow (cash flow from operations less capital expenditure) at the end of fiscal 2012 stood at $392.0 million compared with $425.7 million at the end of fiscal 2011.
At the end of fiscal 2012, Amdocs had approximately $1,118.2 million in cash and marketable securities and $200 million of outstanding debt on its balance sheet compared with $1,173.5 million of cash and marketable securities and $250 million of outstanding debt at the end of fiscal 2011.
Segment Wise Results
Service revenue was $798.1 million, up 2.24% year over year. License revenue was approximately $24.0 million, down 24% year over year. Technologically, Customer Experience Systems revenue was $783.1 million, up 4.9% year over year. Directory revenue was $39.0 million, showing an 18.1% yearly drop. The company’s core Managed Services revenue came in at $423.7 million, up 10.1% year over year.
Geographically, North America generated $570.4 million, down 2.5% year over year; Europe generated $113.1 million, up 10.9% year over year; while the rest of the world contributed the remaining $138.6 million, up 10.8% year over year. Revenue from the emerging markets came in at $99.9 million, showing an annualized growth of 25.7%.
Financial Outlook
Management expects the first quarter fiscal 2012 revenues to be in the range of $810 -840 million. Earnings per share, on a GAAP basis, are expected between 54–64 cents. Moreover, non-GAAP earnings per share, including 6–7 cents per share of equity-based compensation expense, are projected in the range of 68–74 cents.
For fiscal 2013, Amdocs expects its total revenue to grow by approximately 2–5% year over year and its non-GAAP earnings per share to increase by at least 5–8% year over year.
Recommendation
We maintain our long-term Neutral recommendation on Amdocs Ltd. Currently, the company retains a Zacks#3 Rank, implying a short-term Hold rating.
Read the full Analyst Report on T
Read the full Analyst Report on S
Read the full Analyst Report on DOX